Form 4: Precigen CEO Helen Sabzevari Exercises 250k RSU Grant

Precigen President and CEO Helen Sabzevari acquired 250,000 shares of common stock following the vesting of restricted stock units.

Summary

• Helen Sabzevari, President and CEO of Precigen, Inc., acquired 250,000 shares of common stock on May 23, 2026.
• The acquisition resulted from the vesting of restricted stock units (RSUs) granted on June 26, 2025.
• Following this transaction, the reporting person holds a total of 3,888,122 shares of Precigen common stock.
• The transaction represents 50% of the original RSU grant, with the remainder scheduled to vest in equal quarterly installments over the next three years.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation and does not indicate a change in company strategy or financial health.

Positives

• The CEO maintains a significant equity stake of 3,888,122 shares, aligning management interests with shareholders.

Negatives

• None identified in this filing.

Risks

• Future vesting of remaining RSUs may lead to potential dilution or future selling activity by the executive.

Future Outlook

The remaining 50% of the June 26, 2025 RSU grant will vest in equal quarterly installments over the three-year period following May 23, 2026.

Management Comments

• Each restricted stock unit represents a contingent right to receive one share of Precigen common stock.

Industry Context

StockSavvy.ai notes that executive equity vesting is a standard component of compensation packages in the biotechnology sector, intended to incentivize long-term retention and performance.

Comparison to Industry Standards

• The vesting schedule and equity ownership levels are consistent with standard executive compensation practices for mid-cap biotechnology firms.

Stakeholder Impact

• Shareholders may note the continued alignment of the CEO's interests through significant equity holdings.

Next Steps

• Quarterly vesting of remaining RSU grants over the next three years.

Key Dates

Keywords

Precigen, PGEN, Insider Trading, Form 4, Helen Sabzevari, Equity Compensation